About Omega Therapeutics
Omega Therapeutics is a company based in Cambridge (United States) founded in 2016 by David Berry. Omega Therapeutics has raised $211 million across 3 funding rounds from investors including Fidelity Investments, Mirae Asset and BlackRock. The company has 93 employees as of December 31, 2023. Omega Therapeutics operates in a competitive market with competitors including Denali Therapeutics, MiRagen, Poseida Therapeutics, Juno Therapeutics and Castle Biosciences, among others.
- Headquarter Cambridge, United States
- Employees 93 as on 31 Dec, 2023
- Founders David Berry
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Omega Therapeutics, Inc.
-
Annual Revenue
$3.09 M (USD)49as on Dec 31, 2023
-
Net Profit
-$97.43 M (USD)5as on Dec 31, 2023
-
EBITDA
-$100.26 M (USD)2as on Dec 31, 2023
-
Total Equity Funding
$211 M (USD)
in 3 rounds
-
Latest Funding Round
$126 M (USD), Series C
Mar 30, 2021
-
Investors
Fidelity Investments
& 7 more
-
Employee Count
93
as on Dec 31, 2023
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Omega Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Omega Therapeutics
Omega Therapeutics has successfully raised a total of $211M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $126 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Omega Therapeutics
Omega Therapeutics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, Mirae Asset and BlackRock.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Long-term private equity investments in transformational opportunities are pursued.
|
Locked | Locked | Locked | |
|
Private equity fund focused on the biotechnology sector
|
Locked | Locked | Locked | |
|
Life sciences-focused venture capital firm
|
Locked | Locked | Locked |
Investor details for Omega Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Omega Therapeutics
Investment portfolio details for Omega Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Omega Therapeutics
Detailed financials for Omega Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Omega Therapeutics Comparisons
Peer comparison for Omega Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Omega Therapeutics
Omega Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, MiRagen, Poseida Therapeutics, Juno Therapeutics and Castle Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| Locked | Locked | Locked |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
Detailed competitors of Omega Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Omega Therapeutics
Complete news archive for Omega Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Omega Therapeutics
Omega Therapeutics was founded in 2016.
Omega Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Omega Therapeutics is a funded company, having raised a total of $211M across 3 funding rounds to date.
As of Dec 31, 2023, the latest employee count at Omega Therapeutics is 93.
Annual revenue of Omega Therapeutics is $3.09M as on Dec 31, 2023.
Omega Therapeutics was founded in 2016 and is based in Cambridge, United States. A proprietary platform known as GenomStats is employed to regulate genomic expression without modifying nucleic acid sequences. Focus is placed on precision medicine applications for rare genetic diseases, immunology, inflammation, metabolic disorders, and oncology. Operations center on advancing therapeutic solutions in the biotechnology sector.
Omega Therapeutics's top competitors include Juno Therapeutics, Poseida Therapeutics and Denali Therapeutics.
Omega Therapeutics has 8 investors. Key investors include Fidelity Investments, Mirae Asset, BlackRock, TD Securities, and Flagship Pioneering.